Malaria vaccines - The long synthetic peptide approach: Technical and conceptual advancements.
This review describes the advances in malaria antigen discovery and vaccine development using the long synthetic peptide platforms that have been made available during the past 5 years. The most recent technical developments regarding peptide synthesis with the optimized production of large synthetic fragments are discussed. Clinical trials of long synthetic peptides are also reviewed. These trials demonstrated that long synthetic peptides are safe and immunogenic when formulated with various adjuvants. In addition, long synthetic peptides can elicit an antibody response in humans and have demonstrated inhibitory activity against parasite growth in vitro. Finally, new approaches to exploit the abundance of genomic data and the flexibility and speed of peptide synthesis are proposed.
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Sope
S
Olugbile
Catherine
C
Habel
Catherine
C
Servis
François
F
Spertini
Antonio
A
Verdini
Giampietro
G
Corradin
D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D000953:Antigens, Protozoan / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D008288:Malaria / Q000276:immunology / Q000517:prevention & control; D017780:Malaria Vaccines / Q000737:chemistry* / Q000627:therapeutic use; D010455:Peptides / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D010963:Plasmodium falciparum / Q000276:immunology
D000276:Adjuvants, Immunologic; D000953:Antigens, Protozoan; D017780:Malaria Vaccines; D010455:Peptides